Gastroesophageal Junction Cancer clinical trials at UCSD
2 research studies open to eligible people
Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
open to eligible people ages 18 years and up
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck cancer and metastatic colorectal cancer (mCRC). The study will further assess the safety, tolerability, PK, PD, immunogenicity, and anti-tumor activity of MCLA-158 in monotherapy or in combination with other therapies.
La Jolla, California and other locations
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
open to eligible people ages 18 years and up
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.
La Jolla, California and other locations
Last updated: